Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Stock Based Compensation

v3.10.0.1
Note 4 - Stock Based Compensation
3 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Note
4.
Stock Based Compensation
 
The Company recorded
$538,524
of compensation expense related to current and past restricted stock grants and the Company’s Employee Stock Purchase Plan (“ESPP”) for the
three
months ended
December 31, 2018
of which
$507,284
is included in selling, general and administrative expense, and
$31,240
is included in cost of sales. The Company recorded
$483,287
of compensation expense related to current and past equity awards for the
three
months ended
December 31, 2017
of which
$441,257
was included in selling, general and administrative expense, and
$42,030
was included in cost of sales. As of
December 31, 2018,
$3,474,499
of total unrecognized compensation expense related to non-vested awards is expected to be recognized over a period of approximately
5.7
years.
 
Stock Options
 
The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options granted. During the
three
months ended
December 31, 2018,
the Company granted employees non-qualified stock options to purchase an aggregate of
172,000
shares of common stock with a weighted average contractual term of
four
years, a
three
year vesting term, and a weighted average exercise price of
$12.17.
There were
no
stock options granted during the
three
months ended
December 31, 2017.
The weighted-average fair value at the grant date for options issued during the
three
months ended
December 31, 2018
was
$3.53.
 
This fair value was estimated at the grant date using the assumptions listed below:
 
    Three months ended December 31, 2018
Dividend yield  
0%
Weighted average expected volatility  
37.77%
Weighted average risk-free interest rate  
2.92%
Weighted average expected life (years)  
3.0
Vesting period (years)  
3.0
 
The expected stock price volatility is based on the historical volatility of the Company’s stock for a period approximating the expected life. The expected life represents the period of time that options are expected to be outstanding after their grant date. The risk-free interest rate reflects the interest rate at grant date on
zero
-coupon U.S. governmental bonds having a remaining life similar to the expected option term.
 
Options are generally granted at fair market values determined on the date of grant and vesting normally occurs over a
three
to
five
-year period. However, options granted to directors have a
one
year vesting period and a
six
-year contractual term. The maximum contractual term is normally
six
years. Shares issued upon exercise of a stock option are issued from the Company’s authorized but unissued shares.
 
The following is a summary of stock option activity during the
three
months ended
December 31, 2018:
 
    Number of options   Weighted average exercise price
Outstanding as of September 30, 2018    
138,500
    $
10.99
 
Granted    
172,000
     
12.17
 
Exercised    
(3,750
)    
2.58
 
Cancelled or Forfeited    
-
     
-
 
Outstanding as of December 31, 2018    
306,750
    $
11.76
 
 
The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. As of
December 31, 2018,
the weighted average remaining contractual term for all outstanding and exercisable stock options was
1.9
years and their aggregate intrinsic value was
$196,345.
During the
three
months ended
December 31, 2018,
the Company received proceeds of
$17
from the exercise of
3,750
stock options. During the
three
months ended
December 31, 2017,
exercised stock options totaled
3,500
shares, resulting in
$3,249
of proceeds to the Company.
 
Restricted Stock
 
The Company’s
2007
Stock Compensation Plan permits its Compensation Committee to grant stock-based awards, including stock options and restricted stock, to key employees and non-employee directors. The Company has made restricted stock grants that vest over
one
to
ten
years.
 
There were
no
restricted stock awards granted during the
three
months ended
December 31, 2018
and
December 31, 2017.
Restricted stock transactions during the
three
months ended
December 31, 2018
are summarized as follows:
 
    Number of shares   Weighted average grant date fair value
Unvested shares as of September 30, 2018    
248,613
    $
14.65
 
Granted    
-
     
-
 
Vested    
(1,700
)    
13.64
 
Forfeited    
(3,838
)    
14.49
 
Unvested as of December 31, 2018    
243,075
    $
14.66
 
 
Employee Stock Purchase Plan
 
Clearfield, Inc.’s ESPP allows participating employees to purchase shares of the Company’s common stock at a discount through payroll deductions. The ESPP is available to all employees subject to certain eligibility requirements. Terms of the ESPP provide that participating employees
may
purchase the Company’s common stock on a voluntary after-tax basis. Employees
may
purchase the Company’s common stock at a price that is
no
less than the lower of
85%
of the fair market value of
one
share of common stock at the beginning or end of each stock purchase period or phase. The ESPP is carried out in
six
month phases, with phases beginning on
January 1
and
July 1
of each calendar year. For the phases that ended on
December 31, 2018
and
December 31, 2017,
employees purchased
17,312
and
14,242
shares at a price of
$8.43
and
$10.41
per share, respectively. After the employee purchase on
December 31, 2018,
69,769
shares of common stock were available for future purchase under the ESPP.